Piceatannol suppresses the metastatic potential of MCF10A human breast epithelial cells harboring mutated H-ras by inhibiting MMP-2 expression

International Journal of Molecular Medicine

Volumn 32, Issue 4, 2013, Pages 775-784

  Song, Nu Ry ^a,b   Hwang, Mun Kyung ^a,b   Heo, Yong Seok ^c   Lee, Ki Won ^a,b   Lee, Hyong Joo ^a  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

H ras; Matrix metalloproteinase 2; Metastasis; Phosphatidylinositol 3 kinase; Piceatannol

Indexed keywords

GELATINASE A; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PICEATANNOL; PROTEIN KINASE B; RESVERATROL;

ARTICLE; BREAST EPITHELIUM; CELL INVASION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; EX VIVO STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; METASTASIS POTENTIAL; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; GENES, RAS; HUMANS; MATRIX METALLOPROTEINASE 2; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; STILBENES; WINE;

EID: 84883402447     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1449     Document Type: Article

References (47)

1. Sporn MB: The war on cancer. Lancet 347: 1377-1381, 1996.
2. Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130-6138, 1990.
3. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
4. Sato H, Takino T, Okada Y, et al: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61-65, 1994.
5. McCawley LJ and Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6: 149-156, 2000.
6. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119, 2001.
7. Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289-303, 1990.
8. Tryggvason K, Hoyhtya M and Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24: 209-218, 1993.
9. Shin I, Kim S, Song H, Kim HR and Moon A: H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 280: 14675-14683, 2005.
10. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours. Int J Oncol 7: 413-421, 1995.
11. Clair T, Miller WR and Cho-Chung YS: Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 47: 5290-5293, 1987.
12. Clark GJ and Der CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35: 133-144, 1995.
13. Watson DM, Elton RA, Jack WJ, Dixon JM, Chetty U and Miller WR: The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat 17: 161-169, 1991.
14. Moon A, Kim MS, Kim TG, et al: H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer 85: 176-181, 2000.
15. Dhillon AS, Meikle S, Yazici Z, Eulitz M and Kolch W: Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J 21: 64-71, 2002.
16. Wymann MP, Zvelebil M and Laffargue M: Phosphoinositide 3-kinase signalling - which way to target? Trends Pharmacol Sci 24: 366-376, 2003
17. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
18. Chang F, Lee JT, Navolanic PM, et al: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17: 590-603, 2003.
19. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
20. Sliva D, Rizzo MT and English D: Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem S277: 3150-3157, 2002.
21. Sizemore N, Leung S and Stark GR: Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19: 4798-4805, 1999.
22. Estrov Z, Shishodia S, Faderl S, et al: Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 02: 987-995, 2003.
23. Mgbonyebi OP, Russo J and Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865-869, 1998.
24. Hsieh TC and Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109-115, 1999.
25. Potter GA, Patterson LH, Wanogho E, et al: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778, 2002.
26. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S and Aggarwal BB: Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol 169: 6490-6497, 2002.
27. Roupe KA, Remsberg CM, Yanez JA and Davies NM: Pharmacometrics of stilbenes: seguing towards the clinic. Curr Clin Pharmacol 1: 81-101, 2006.
28. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
29. Briviba K, Pan L and Rechkemmer G: Red wine polyphenols inhibit the growth of colon carcinoma cells and modulate the activation pattern of mitogen-activated protein kinases. J Nutr 132: 2814-2818, 2002.
30. Hakimuddin F, Paliyath G and Meckling K: Treatment of mcf-7 breast cancer cells with a red grape wine polyphenol fraction results in disruption of calcium homeostasis and cell cycle arrest causing selective cytotoxicity. J Agric Food Chem 54: 7912-7923, 2006.
31. Saiko P, Szakmary A, Jaeger W and Szekeres T: Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 658: 68-94, 2008
32. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
33. Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895-904, 2006.
34. Liotta LA, Thorgeirsson UP and Garbisa S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1: 277-288, 1982.
35. Liotta LA: Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 46: 1-7, 1986.
36. Geiger TR and Peeper DS: Metastasis mechanisms. Biochim Biophys Acta 1796: 293-308, 2009.
37. Bourne HR, Sanders DA and McCormick F: The GTPase superfamily: conserved structure and molecular mechanism. Nature 349: 117-127, 1991.
38. Malumbres M and Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231, 2001.
39. Feig LA and Buchsbaum RJ: Cell signaling: life or death decisions of ras proteins. Curr Biol 12: R259-R261, 2002.
40. Inukai K, Funaki M, Ogihara T, et al: p85alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and p85alpha, with different PI 3-kinase activity elevating responses to insulin. J Biol Chem 272: 7873-7882, 1997.
41. Ueki K, Algenstaedt P, Mauvais-Jarvis F and Kahn CR: Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit. Mol Cell Biol 20: 8035-8046, 2000.
42. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
43. Rodriguez-Viciana P, Warne PH, Dhand R, et al: Phospha-tidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532, 1994.
44. Walker EH, Pacold ME, Perisic O, et al: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6: 909-919, 2000.
45. Walker EH, Perisic O, Ried C, Stephens L and Williams RL: Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402: 313-320, 1999.
46. Choi KH, Kim JE, Song NR, et al: Phosphoinositide-3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res 85: 836-844, 2010.
47. Frojdo S, Cozzone D, Vidal H and Pirola L: Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J 406: 511-518, 2007.